持续气道正压通气联合下颌前移矫治器(PAPMAT):比较两种成熟阻塞性睡眠呼吸暂停疗法联合应用获益与成本的自适应随机交叉试验研究方案
PAPMAT是一项在区域NHS睡眠服务中心招募中重度OSA患者的两臂随机交叉试验,比较单独CPAP与CPAP联合MAD各12周(含2周适应期)对CPAP依从性的影响,并评估OSA严重度、患者报告结局、治疗偏好、医疗服务使用及成本效果。
要点
- 研究比较单独CPAP与CPAP+MAD两种方案,每臂12周(含2周适应期),主要结局为CPAP依从性。
- 研究对象为初始滴定后CPAP压力需求较高的中重度OSA患者。
- 次要结局包括OSA严重度、主观日间嗜睡、生活质量、治疗偏好及医疗服务使用,并做成本效果分析。
核心结论
- 若干预在该符合标准CPAP治疗条件的OSA患者人群中显示能有效且具成本效果地改善依从性,则引入现有OSA治疗路径相对直接。
研究设计与样本
- 两臂随机交叉试验,在区域NHS睡眠服务中心连续招募开始CPAP治疗的中重度OSA患者,纳入初始滴定后CPAP压力需求较高且符合全部入组标准并知情同意者。
- 两臂分别为单独CPAP和CPAP+MAD,每臂12周,包括2周适应期;CPAP机器为自动滴定型并具备数据下载功能。
关键数值与推荐
- 主要结局为CPAP依从性;次要结局包括OSA严重度指标、患者报告结局(含主观日间嗜睡、生活质量)、试验退出时治疗偏好及医疗服务使用。
- 将进行成本效果分析。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obstructive sleep apnoea (OSA) involves repeated breathing pauses during sleep due to upper airway obstruction. It causes excessive daytime sleepiness and has other health impacts. Continuous positive airway pressure (CPAP) therapy is effective first line treatment for moderate to severe OSA. Unfortunately, many patients have difficulty tolerating CPAP and pressure intolerance is probably an important contributing factor. Mandibular advancement devices (MAD) are an alternative to CPAP. They are worn in the mouth during sleep to reduce airway obstruction. There is some evidence that, when used in combination with CPAP, MADs improve airway anatomy enough to reduce the CPAP pressure required to treat OSA and that this combination therapy could improve CPAP adherence. METHODS: Consecutive patients starting on CPAP for moderate to severe OSA will be recruited at a regional NHS sleep service. Patients with high CPAP pressure requirements after initial titration, who satisfy all entry criteria and consent to participate, will undertake a 2-arm randomised crossover trial. The arms will be (i) standalone CPAP and (ii) CPAP + MAD therapy. Each arm will last 12 weeks, including 2 weeks acclimatisation. CPAP machines will be auto-titrating and with facility for data download, so the impact of MAD on CPAP pressure requirements and CPAP adherence can be easily measured. The primary outcome will be CPAP adherence. Secondary outcomes will include measures of OSA severity, patient-reported outcome measures including subjective daytime sleepiness, quality of life, and treatment preference at the trial exit and health service use. Cost-effectiveness analyses will be undertaken. DISCUSSION: If the intervention is shown to be effective and cost-effective in improving adherence in this standard CPAP-eligible OSA patient population it would be relatively straightforward to introduce into existing OSA treatment pathways, within the wider NHS and more widely. Both MAD and CPAP are already used by sleep services so their combination would require only minor adjustments to existing clinical pathways. It would be straightforward to disseminate the results of the study through regional, national, and international respiratory meetings. The health economics analysis would provide cost-effectiveness data to inform service planning and clinical guidelines through policy briefing papers, including those by NICE and SIGN. TRIAL REGISTRATION: PAPMAT was registered with ISRCTN prior to recruitment beginning (ISRCTN Registry 2021): https://www.isrctn.com/ISRCTN33966032 . Registered on 17th November 2021.
引用
- Law M, Villar S, Oscroft N, et al. Continuous Positive Airway Pressure plus Mandibular Advancement Therapy (PAPMAT): study protocol for an adaptive randomised crossover trial comparing the benefits and costs of combining two established treatments for obstructive sleep apnoea. Trials. 2023. PMID: 37488626. doi:10.1186/s13063-023-07484-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。